Mentioned On
Episode Mentions
BioSpace · May 13, 2026
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
“Received FDA priority review voucher; BizZengri approved in two days for ultra-rare bile duct cancer”
FDA Commissioner leadership transition and removalRegulatory uncertainty and HHS agency turnoverCommissioner's National Priority Review voucher program
View Analysis